Endovascular brachytherapy using 125I seeds strand combined with transarterial chemoembolization, lenvatinib, and camrelizumab for unresectable hepatocellular carcinoma with hepatic vein tumor thrombus
Brachytherapy · 2026-11
DOI: 10.1016/j.brachy.2026.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026-11. Verfasst von Min Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Interventional Radiology, Shanghai Insti…. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the safety and efficacy of Iodine-125(125I) seed strand implantation in combination with transarterial chemoembolization (TACE), lenvatinib, and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC) with hepatic vein tumor thrombus (HVTT). METHODS AND MATERIALS: From January 2020 to December 2023, 76 uHCC patients with HVTT were included in this single-center retrospective study. Thirty-six patients underwent 125I seed strand implantation combined with TACE, lenvatinib, and camrelizumab (group A), whereas 40 patients received TACE combined with lenvatinib and camrelizumab (group B). Outcome measures comprised with technique success rate, overall response rate (ORR), disease control rate (DCR), overall survival (OS) time, progression-free survival (PFS) time, and adverse event occurrence rate. RESULTS: The technique was successfully performed in all patients. The mean intended dose (r, irradiation range = 10 mm; z, irradiation duration = 240 days) was 64.0 ± 0.3 Gy. No grade 3 or 4 adverse events related to 125I seed strand implantation occurred in group A. The ORR and DCR of HVTT were significantly higher in group A compared with group B (ORR, 72.2% vs. 15.0%, p < 0.001; DCR, 88.9% vs. 35%, p < 0.001). And the median OS time and PFS time were significant longer in group A compared with group B (OS, 22.1 ± 2.4 vs. 14.0 ± 1.7 months, p < 0.001; PFS, 17.6 ± 0.3 vs. 8.0 ± 0.6 months, p < 0.001). In the multivariate Cox regression analysis, treatment regimen was an independent prognostic factor for OS. No serious complications related to interventional treatment, including acute hepatic failure, liver abscess, intraperitoneal bleeding, and radiation hepatitis was observed. CONCLUSIONS: 125I seeds strand combined with TACE, lenvatinib, and camrelizumab as the treatment strategy for uHCC patients with HVTT is safe and effective.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Interventional Radiology, Shanghai Institute of Medical Imaging, Shanghai, China; Department of Interventional…
Zitieren
APA
Li, M., Wan, J. C., Zhang, W., Yan, Z. P., Qu, X. D., & Zhang, Z. H. (2026). Endovascular brachytherapy using 125I seeds strand combined with transarterial chemoembolization, lenvatinib, and camrelizumab for unresectable hepatocellular carcinoma with hepatic vein tumor thrombus. Brachytherapy. https://doi.org/10.1016/j.brachy.2026.09.003
Vancouver
Li M, Wan JC, Zhang W, Yan ZP, Qu XD, Zhang ZH. Endovascular brachytherapy using 125I seeds strand combined with transarterial chemoembolization, lenvatinib, and camrelizumab for unresectable hepatocellular carcinoma with hepatic vein tumor thrombus. Brachytherapy. 2026. doi:10.1016/j.brachy.2026.09.003
BibTeX
@article{Li2026,
author = {Li, Min and Wan, Jun-Cheng and Zhang, Wen and Yan, Zhi-Ping and Qu, Xu-Dong and Zhang, Zi-Han},
title = {Endovascular brachytherapy using 125I seeds strand combined with transarterial chemoembolization, lenvatinib, and camrelizumab for unresectable hepatocellular carcinoma with hepatic vein tumor thrombus},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2026.09.003}
}
EUVIMED